1.
Cancer Invest
; 33(7): 276-85, 2015.
Article
in English
| MEDLINE
| ID: mdl-25951372
ABSTRACT
New therapies for prostate cancer have emerged over the past three years. Nevertheless, none of these agents is curative, and unfortunately, patients often ultimately develop resistance to these agents. Therefore, the development of innovative and effective therapies that overcome these resistances is necessary. Unfortunately, the results of a phase III trial evaluating docetaxel in combination with targeted therapies demonstrated no difference in survival. Moreover, scarce data on the combination of a targeted therapy with new agents are currently available. New trials are investigating these possible combination treatments; the results of these (on-going) clinical studies are awaited.
Subject(s)
Antineoplastic Agents/pharmacology , Molecular Targeted Therapy/methods , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/genetics , Animals , Antineoplastic Agents/therapeutic use , Clinical Trials as Topic , Drug Evaluation, Preclinical , Drug Resistance, Neoplasm , Gene Expression Regulation, Neoplastic/drug effects , Humans , Male , Treatment Outcome
2.
J Am Geriatr Soc
; 62(11): 2204-5, 2014 Nov.
Article
in English
| MEDLINE
| ID: mdl-25413190